Nestle Develops Products for Users of GLP-1 Weight-Loss Drugs Using AI
Nestle is developing new products targeting users of GLP-1 weight-loss drugs like Ozempic and Wegovy, using artificial intelligence and nutritional science to address side effects such as muscle loss and facial fat reduction. The company views this as a business opportunity amid concerns that appetite-suppressing drugs could reduce demand for packaged foods. Nestle's Chief Technology Officer Stefan Palzer highlighted the use of AI to analyze clinical research and tailor products for this growing consumer segment.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 39/100.
Outlets measured: economictimes, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 17 Aug, 06:21 am. Other outlets followed.
- 1